Table 1.
Demographics of participants who completed study.
| PKG+ N = 75 |
PKG− N = 79 |
||||
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | P value | Δ (SEM) | 95% CI | |
| Age | 68.2 ± 4.5 | 67.4 ± 4.9 | 0.28 | 0.8 ± 0.8 | −0.7 to 2.3 |
| Gender (F/M) | 40/35 | 32/47 | |||
| Years to diag. | 6.4 ± 4 | 6.3 ± 3.6 | 0.90 | 0.1 ± 0.6 | −1.1 to 1.3 |
| LEDDa | 675 ± 330 | 760 ± 325 | 0.11 | −85 ± 54 | −190 to 20 |
| UPDRSb I | 10.5 ± 4.9 | 11.2 ± 6.1 | 0.50 | −0.6 ± 0.9 | −2.4 to 1.2 |
| UPDRS II | 9.5 ± 5.8 | 10.7 ± 6.5 | 0.27 | −1.1 ± 1.0 | −3.1 to 0.9 |
| UPDRS III | 35.1 ± 9.6 | 35.8 ± 11.3 | 0.65 | −0.8 ± 1.7 | −4.1 to 2.6 |
| UPDRS IV | 5.0 ± 3.8 | 4.6 ± 3.6 | 0.56 | 0.4 ± 0.6 | −0.8 to 1.5 |
| UPDRS Total | 59.6 ± 16.9 | 62.3 ± 19.6 | 0.36 | −2.7 ± 3.0 | −8.6 to 3.1 |
| PDQc 39 | 26.9 ± 16.8 | 29.6 ± 19.1 | 0.37 | −2.7 ± 2.9 | −8.4 to 3.1 |
| H&Yd | 1.9 ± 0.6 | 2.0 ± 0.6 | 0.39 | −0.1 ± 0.1 | −0.3 to 0.1 |
| MoCAd | 26.5 ± 2.1 | 25.9 ± 2.5 | 0.10 | 0.6 ± 0.4 | −0.1 to 1.4 |
| SENS PDf | 11.1 ± 4.9 | 12.1 ± 5.2 | 0.26 | −0.9 ± 0.8 | −2.6 to 0.7 |
aLevodopa Equivalent Daily Dose, bMovement Disorder Society Unified Parkinson’s Disease Rating Scale. cParkinson’s Disease Quality of Life 39 Questions. dHohn and Yahr scale. eMontreal Cognitive Assessment. fSeverity of predominantly Non-dopaminergic Symptoms in Parkinson’s Disease.